{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T08:50:10Z","timestamp":1793350210136,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100008270","name":"Lantheus Medical Imaging","doi-asserted-by":"publisher","award":["Lantheus Medical Imaging"],"award-info":[{"award-number":["Lantheus Medical Imaging"]}],"id":[{"id":"10.13039\/100008270","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00259-025-07133-1","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T09:18:45Z","timestamp":1739179125000},"page":"2335-2342","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Utility of 18F-DCFPyL PET for local staging for high or very high risk prostate cancer for patients undergoing radical prostatectomy"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5506-5755","authenticated-orcid":false,"given":"Eric V.","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0699-1899","authenticated-orcid":false,"given":"Edward M.","family":"Schaeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Kaushik Shankar","family":"Ramesh Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoji","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximing J.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Mana-Ay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariavittoria","family":"Vescovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Kate","family":"Keeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Casalino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masha","family":"Kocherginsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4028-010X","authenticated-orcid":false,"given":"Hiten D.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7044-9688","authenticated-orcid":false,"given":"Ashley E.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatice","family":"Savas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"key":"7133_CR1","doi-asserted-by":"publisher","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","DOI":"10.3322\/caac.21820"},{"key":"7133_CR2","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1200\/jco.2009.26.0133","volume":"28","author":"MR Cooperberg","year":"2010","unstructured":"Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010;28:1117\u201323. https:\/\/doi.org\/10.1200\/jco.2009.26.0133.","journal-title":"J Clin Oncol"},{"key":"7133_CR3","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.1158\/1078-0432.Ccr-20-4573","volume":"27","author":"MJ Morris","year":"2021","unstructured":"Morris MJ, Rowe SP, Gorin MA, Saperstein L, Pouliot F, Josephson D, et al. Diagnostic performance of (18)F-DCFPyL-PET\/CT in men with biochemically recurrent prostate Cancer: results from the CONDOR Phase III, Multicenter Study. Clin Cancer Res. 2021;27:3674\u201382. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-4573.","journal-title":"Clin Cancer Res"},{"key":"7133_CR4","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/s0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208\u201316. https:\/\/doi.org\/10.1016\/s0140-6736(20)30314-7.","journal-title":"Lancet"},{"key":"7133_CR5","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/ju.0000000000001698","volume":"206","author":"KJ Pienta","year":"2021","unstructured":"Pienta KJ, Gorin MA, Rowe SP, Carroll PR, Pouliot F, Probst S, et al. A phase 2\/3 prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET\/CT with (18)F-DCFPyL in prostate Cancer patients (OSPREY). J Urol. 2021;206:52\u201361. https:\/\/doi.org\/10.1097\/ju.0000000000001698.","journal-title":"J Urol"},{"key":"7133_CR6","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.eururo.2023.06.018","volume":"84","author":"DS Surasi","year":"2023","unstructured":"Surasi DS, Eiber M, Maurer T, Preston MA, Helfand BT, Josephson D, et al. Diagnostic performance and safety of Positron Emission Tomography with (18)F-rhPSMA-7.3 in patients with newly diagnosed unfavourable Intermediate- to very-high-risk prostate Cancer: results from a phase 3, prospective, Multicentre Study (LIGHTHOUSE). Eur Urol. 2023;84:361\u201370. https:\/\/doi.org\/10.1016\/j.eururo.2023.06.018.","journal-title":"Eur Urol"},{"key":"7133_CR7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/ju.0000000000003493","volume":"210","author":"AB Jani","year":"2023","unstructured":"Jani AB, Ravizzini GC, Gartrell BA, Siegel BA, Twardowski P, Saltzstein D, et al. Diagnostic performance and safety of (18)F-rhPSMA-7.3 Positron Emission Tomography in Men with suspected prostate Cancer recurrence: results from a phase 3, prospective, Multicenter Study (SPOTLIGHT). J Urol. 2023;210:299\u2013311. https:\/\/doi.org\/10.1097\/ju.0000000000003493.","journal-title":"J Urol"},{"key":"7133_CR8","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate Cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024;86:148\u201363. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027.","journal-title":"Eur Urol"},{"key":"7133_CR9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.eururo.2015.07.029","volume":"70","author":"M de Rooij","year":"2016","unstructured":"de Rooij M, Hamoen EH, Witjes JA, Barentsz JO, Rovers MM. Accuracy of magnetic resonance imaging for local staging of prostate Cancer: a diagnostic Meta-analysis. Eur Urol. 2016;70:233\u201345. https:\/\/doi.org\/10.1016\/j.eururo.2015.07.029.","journal-title":"Eur Urol"},{"key":"7133_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2967\/jnumed.123.266005","volume":"65","author":"F Wang","year":"2024","unstructured":"Wang F, Liu C, Vidal I, Mana-Ay M, Voter AF, Solnes LB, et al. Comparison of multiple segmentation methods for volumetric delineation of primary prostate Cancer with prostate-specific membrane Antigen-targeted (18)F-DCFPyL PET\/CT. J Nucl Med. 2024;65:87\u201393. https:\/\/doi.org\/10.2967\/jnumed.123.266005.","journal-title":"J Nucl Med"},{"key":"7133_CR11","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1097\/ju.0000000000002293","volume":"207","author":"S Raveenthiran","year":"2022","unstructured":"Raveenthiran S, Yaxley WJ, Franklin T, Coughlin G, Roberts M, Gianduzzo T, et al. Findings in 1,123 men with preoperative (68)Ga-Prostate-specific membrane Antigen Positron Emission Tomography\/Computerized Tomography and Multiparametric Magnetic Resonance Imaging Compared to totally embedded radical prostatectomy histopathology: implications for the diagnosis and management of prostate Cancer. J Urol. 2022;207:573\u201380. https:\/\/doi.org\/10.1097\/ju.0000000000002293.","journal-title":"J Urol"},{"key":"7133_CR12","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1002\/pros.24420","volume":"82","author":"T Ucar","year":"2022","unstructured":"Ucar T, Gunduz N, Demirci E, Culpan M, Gunel H, Kir G, et al. Comparison of 68Ga-PSMA PET\/CT and mp-MRI in regard to local staging for prostate cancer with histopathological results: a retrospective study. Prostate. 2022;82:1462\u20138. https:\/\/doi.org\/10.1002\/pros.24420.","journal-title":"Prostate"},{"key":"7133_CR13","doi-asserted-by":"publisher","first-page":"382","DOI":"10.21037\/tau.2020.03.06","volume":"9","author":"M Chen","year":"2020","unstructured":"Chen M, Zhang Q, Zhang C, Zhou YH, Zhao X, Fu Y, et al. Comparison of (68)Ga-prostate-specific membrane antigen (PSMA) positron emission tomography\/computed tomography (PET\/CT) and multi-parametric magnetic resonance imaging (MRI) in the evaluation of tumor extension of primary prostate cancer. Transl Androl Urol. 2020;9:382\u201390. https:\/\/doi.org\/10.21037\/tau.2020.03.06.","journal-title":"Transl Androl Urol"},{"key":"7133_CR14","doi-asserted-by":"publisher","unstructured":"Combes AD, Palma CA, Calopedos R, Wen L, Woo H, Fulham M, et al. PSMA PET-CT in the diagnosis and staging of prostate Cancer. Diagnostics (Basel). 2022;12. https:\/\/doi.org\/10.3390\/diagnostics12112594.","DOI":"10.3390\/diagnostics12112594"},{"key":"7133_CR15","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/j.0006-341x.2000.00345.x","volume":"56","author":"W Leisenring","year":"2000","unstructured":"Leisenring W, Alonzo T, Pepe MS. Comparisons of predictive values of binary medical diagnostic tests for paired designs. Biometrics. 2000;56:345\u201351. https:\/\/doi.org\/10.1111\/j.0006-341x.2000.00345.x.","journal-title":"Biometrics"},{"key":"7133_CR16","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.euo.2020.08.008","volume":"5","author":"TFW Soeterik","year":"2022","unstructured":"Soeterik TFW, van Melick HHE, Dijksman LM, K\u00fcsters-Vandevelde H, Stomps S, Schoots IG, et al. Development and External Validation of a Novel Nomogram to predict side-specific extraprostatic extension in patients with prostate Cancer undergoing radical prostatectomy. Eur Urol Oncol. 2022;5:328\u201337. https:\/\/doi.org\/10.1016\/j.euo.2020.08.008.","journal-title":"Eur Urol Oncol"},{"key":"7133_CR17","doi-asserted-by":"publisher","unstructured":"Martini A, Gupta A, Lewis SC, Cumarasamy S, Haines KG 3rd, Briganti A, et al. Development and internal validation of a side-specific, multiparametric magnetic resonance imaging-based nomogram for the prediction of extracapsular extension of prostate cancer. BJU Int. 2018;122:1025\u201333. https:\/\/doi.org\/10.1111\/bju.14353.","DOI":"10.1111\/bju.14353"},{"key":"7133_CR18","doi-asserted-by":"publisher","first-page":"847","DOI":"10.2967\/jnumed.121.262398","volume":"63","author":"I Sonni","year":"2022","unstructured":"Sonni I, Felker ER, Lenis AT, Sisk AE, Bahri S, Allen-Auerbach M, et al. Head-to-Head comparison of (68)Ga-PSMA-11 PET\/CT and mpMRI with a Histopathology Gold Standard in the detection, Intraprostatic Localization, and determination of local extension of primary prostate Cancer: results from a prospective single-center imaging trial. J Nucl Med. 2022;63:847\u201354. https:\/\/doi.org\/10.2967\/jnumed.121.262398.","journal-title":"J Nucl Med"},{"key":"7133_CR19","doi-asserted-by":"publisher","first-page":"6300","DOI":"10.1158\/1078-0432.Ccr-18-0768","volume":"24","author":"B Grubm\u00fcller","year":"2018","unstructured":"Grubm\u00fcller B, Baltzer P, Hartenbach S, D\u2019Andrea D, Helbich TH, Haug AR, et al. PSMA Ligand PET\/MRI for primary prostate Cancer: staging performance and clinical impact. Clin Cancer Res. 2018;24:6300\u20137. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-0768.","journal-title":"Clin Cancer Res"},{"key":"7133_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.eururo.2023.03.001","volume":"84","author":"KM Chow","year":"2023","unstructured":"Chow KM, So WZ, Lee HJ, Lee A, Yap DWT, Takwoingi Y, et al. Head-to-head comparison of the diagnostic accuracy of prostate-specific membrane Antigen Positron Emission Tomography and Conventional Imaging modalities for initial staging of Intermediate- to high-risk prostate Cancer: a systematic review and Meta-analysis. Eur Urol. 2023;84:36\u201348. https:\/\/doi.org\/10.1016\/j.eururo.2023.03.001.","journal-title":"Eur Urol"},{"key":"7133_CR21","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","volume":"7","author":"TA Hope","year":"2021","unstructured":"Hope TA, Eiber M, Armstrong WR, Juarez R, Murthy V, Lawhn-Heath C, et al. Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial. JAMA Oncol. 2021;7:1635\u201342. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3771.","journal-title":"JAMA Oncol"},{"key":"7133_CR22","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s11864-024-01181-9","volume":"25","author":"AB Weiner","year":"2024","unstructured":"Weiner AB, Agrawal R, Valle LF, Sonni I, Kishan AU, Rettig MB, et al. Impact of PSMA PET on prostate Cancer Management. Curr Treat Options Oncol. 2024;25:191\u2013205. https:\/\/doi.org\/10.1007\/s11864-024-01181-9.","journal-title":"Curr Treat Options Oncol"},{"key":"7133_CR23","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s00259-017-3852-8","volume":"45","author":"M Sathekge","year":"2018","unstructured":"Sathekge M, Lengana T, Maes A, Vorster M, Zeevaart J, Lawal I, et al. (68)Ga-PSMA-11 PET\/CT in primary staging of prostate carcinoma: preliminary results on differences between black and white South-africans. Eur J Nucl Med Mol Imaging. 2018;45:226\u201334. https:\/\/doi.org\/10.1007\/s00259-017-3852-8.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07133-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07133-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07133-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T10:18:09Z","timestamp":1748427489000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07133-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["7133"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07133-1","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]},"assertion":[{"value":"22 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Community of Northwestern University (IRB STU00205957-CR0005).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"There are no individual patient data or sensitive data requiring additional consent to publish.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"AER is a consultant and speaker for Lantheus and Blue Earth, both of whom market PSMA targeted tracers for PET imaging. EMS is a consultant for Lantheus. The remainder of the authors declare that they have no financial interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}